A5050455142- Corneal surgery and disorders
- Glaucoma and retinal disorders
- Corneal Surgery and Treatments
- Dermatology and Skin Diseases
- Allergic Rhinitis and Sensitization
- Ocular Surface and Contact Lens
- Ophthalmology and Visual Impairment Studies
- Urticaria and Related Conditions
- Intraocular Surgery and Lenses
- Contact Dermatitis and Allergies
- Platelet Disorders and Treatments
- Neurological Disorders and Treatments
- Ocular Infections and Treatments
- Food Allergy and Anaphylaxis Research
- Retinal Diseases and Treatments
- Congenital limb and hand anomalies
- Cerebral Palsy and Movement Disorders
- Connexins and lens biology
- Herpesvirus Infections and Treatments
- Drug-Induced Adverse Reactions
- Nerve Injury and Rehabilitation
- Leptospirosis research and findings
- Nephrotoxicity and Medicinal Plants
- Acute Ischemic Stroke Management
- Infectious Encephalopathies and Encephalitis
Hôpital Purpan
2011-2024
Université de Toulouse
2014-2024
Institut Toulousain des Maladies Infectieuses et Inflammatoires
2022-2024
Clinique Pasteur
2024
Université Toulouse III - Paul Sabatier
2013-2024
Centre National de la Recherche Scientifique
2022-2024
Inserm
2022-2024
Hôpital Paule de Viguier
2014-2023
Centre Hospitalier Universitaire de Toulouse
2014-2022
Centre de Physiopathologie de Toulouse-Purpan
2012-2015
We compared an iontophoresis riboflavin delivery technique for transepithelial corneal collagen crosslinking (I-CXL) with a conventional CXL (C-CXL).We designed three experimental sets using 152 New Zealand rabbits to study application by charged solution (Ricrolin+) 1-mA current 5 minutes. The first set was compare concentration measured HPLC in corneas after or application. second analyze autofluorescence and stromal modification immediately 14 days I-CXL C-CXL, nonlinear two-photon...
PURPOSE: To compare the efficacy and safety of topography-guided corneal collagen cross-linking (TG-CXL) to conventional CXL (C-CXL) in progressive keratoconus. METHODS: In this prospective, nonrandomized clinical trial, 60 eyes patients were scheduled receive either TG-CXL (30 with deepithelialization focused on cone, riboflavin application for 10 minutes, 30 mW/cm 2 pulsed ultraviolet-A irradiance pattern according topography) or C-CXL treated accordance Dresden protocol). Patients...
Although ocular adverse events are frequent in AD patients treated with dupilumab, their characterization remains limited due to a lack of prospective studies systematic ophthalmological examination. To examine the incidence, characteristics and risk factors dupilumab-induced events. A prospective, multicenter, real-life study adult dupilumab. At baseline, 27 out 181 (14.9%) had conjunctivitis. week 16 (W16), 25 improved conjunctivitis 2 remained stable 34 (18.7%) blepharoconjunctivitis:...
<h3>Background</h3> Corneal intraepithelial dyskeratosis is an extremely rare condition. The classical form, affecting Native American Haliwa-Saponi tribe members, called hereditary benign (HBID). Herein, we present a new form of corneal for which identified the causative gene by using deep sequencing technology. <h3>Methods and results</h3> A seven member Caucasian French family with two affected individuals (6-year-old proband his mother) was ascertained. presented bilateral complete...
Abstract Background Dupilumab is approved for use in moderate‐to‐severe atopic dermatitis (AD) and as an add‐on maintenance treatment patients suffering from severe asthma with type 2 inflammation. Ocular adverse events (OAEs) have been reported dupilumab almost exclusively treated AD. Objectives The objectives of this study were to describe the incidence nature dupilumab‐induced OAEs assess potential predisposing factors. Patients methods We conducted a prospective, single‐centre, real‐life...
Purpose: Corneal crosslinking (CXL) is the standard treatment of progressive keratoconus (KC). We evaluated safety and 10-year outcomes conventional “epithelial-off” CXL for KC first time in a cohort France. Methods: conducted retrospective review patients undergoing (Dresden protocol) our tertiary ophthalmology department from 2006 to 2011 with follow-up. The primary outcome was change preoperative versus postoperative keratometry measured by maximum (Kmax), steep (K2), flat (K1), mean...
To evaluate the success rate, efficacy, and safety of ICD 16.5 mini-scleral gas permeable (GP) contact lens.This prospective study included referred consecutive patients with irregular corneas severe ocular surface disease (OSD) in treatment failure. All were fitted GP lens. Even though we had some limited experience scleral lenses, it was our first Efficacy assessed by comparing best-corrected visual acuity (BCVA) lens to baseline BCVA. A subjective functioning questionnaire (comfort score,...
PURPOSE: To evaluate the efficacy and safety of transepithelial corneal cross-linking (CXL) with supplemental oxygen. METHODS: This was a prospective, non-comparative, pilot cohort study conducted at National Reference Center for Keratoconus (Toulouse, France) on patients progressive keratoconus. Transepithelial, pulsed, accelerated CXL performed in an oxygen-rich atmosphere. Oxygen goggles were applied to eyes maintain high level oxygen during treatment. The main outcome mean change from...
Keratoconus (KC) is a multifactorial progressive ectatic disorder characterized by local thinning of the cornea, leading to decreased visual acuity due irregular astigmatism and opacities. Despite evolution advanced imaging methods, exact etiology KC remains unknown. Our aim was investigate involvement corneal epithelium in pathophysiology disease. Corneal epithelial samples were collected from 23 controls 2 cohorts patients with KC: 22 undergoing crosslinking (early KC) 6 before penetrating...
Purpose.: To characterize the expression of bone morphogenetic protein-1 (BMP-1)/tolloid-like proteinases (collectively called BTPs), which include BMP-1, mammalian tolloid (mTLD), and tolloid-like 1 (mTLL-1) 2 (mTLL-2), as well associated proteins procollagen C-proteinase enhancers (PCPE-1 -2), in corneal scarring. Methods.: Using a mouse full-thickness excision model, wound healing was followed for up to 28 days by transmission electron microscopy, immunohistology (BMP-1/mTLD PCPE-1),...
Purpose To compare the outcomes of transepithelial photorefractive intrastromal corneal crosslinking (CXL) and keratectomy (PRK) in eyes with low myopia. Setting Purpan Hospital, Toulouse, France. Design Prospective case series. Methods Myopic patients a manifest refraction spherical equivalent (MRSE) −1.00 to −2.50 diopters (D) cylindrical component plano −0.75 D were included. The dominant eye had PRK (PRK eyes). nondominant CXL riboflavin (ParaCel Part 1 2), 30 mW/cm2 pulsed ultraviolet-A...
To evaluate the efficacy and safety of combined implantation a monofocal intraocular lens (IOL) in capsular bag with diffractive multifocal IOL designed for sulcus placement (Reverso).Purpan Hospital, Toulouse, Helios Clinic, Saint-Jean-de-Luz, France.Prospective case series.The piggyback was implanted during cataract surgery. Visual acuity, defocus curve, contrast sensitivity, positioning, patient satisfaction were assessed 1-year follow-ups.Fifty-four eyes 27 patients included. At 1-month,...
The association of early-onset non-progressive ataxia and miosis is an extremely rare phenotypic entity occasionally reported in the literature. To date, only one family (two siblings their mother) has benefited from a genetic diagnosis by identification missense heterozygous variant (p.Arg36Cys) ITPR1 gene. This gene encodes inositol 1,4,5-trisphosphate receptor type 1, intracellular channel that mediates calcium release endoplasmic reticulum. Deleterious variants this are known to be...
Abstract Purpose A longitudinal observational multicentric study is conducted in Ophthalmology departments of Gabriel Montpied Hospital Clermont‐Ferrand and Purpan Toulouse. The aim our to evaluate compare the variations riboflavin concentration vivo through fluorophotometry anterior segment, during iontophoresis procedure (I‐CXL) conventional cross‐linking (C‐CXL) for keratoconus patients. Methods Inclusion criteria are patients from 18 40 years old, with progressive a corneal pachymetry...